Selective Tyrosine Functionalization for Pin1 Inhibitor Biomaterials
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, inflammatory diseases, and metabolic diseases are inadequate due to the lack of effective inhibitors for the Pin1 enzyme, which plays a crucial role in their onset and progression.
Innovation Solution
Development of a novel compound represented by formula 1, its isomers, or pharmaceutically acceptable salts, which inhibit Pin1 activity, formulated into pharmaceutical and health functional food compositions for prevention or treatment of these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Pin1 enzyme is inhibited, then cancer progression and metastasis are suppressed, but the compound structure and synthesis complexity increase
Solution Approach 1:
The patent modifies molecular parameters of Pin1 inhibitors by changing substituent groups (R1-R6, Ar, L1-L3) in the core compound structure. This allows optimization of binding affinity and selective inhibition while managing structural complexity through systematic parameter variation rather than creating entirely new molecular architectures.
Solution Approach 2:
The compound structure is divided into distinct functional segments: a core scaffold (formula 1), variable substituent groups (R1-R6), and linkage moieties (L1-L3). This segmentation enables independent optimization of each component's contribution to Pin1 inhibition while simplifying the overall synthesis process by assembling pre-defined modular units.
2Reliability
If Pin1 inhibitor compounds are developed, then therapeutic effectiveness improves, but manufacturing and synthesis difficulty increase
Solution Approach 1:
The patent establishes preliminary synthetic routes by defining the core compound structure (formula 1) and its precursor compounds before final assembly. This preliminary planning allows for optimized synthesis sequences, pre-preparation of building blocks, and anticipation of potential synthesis bottlenecks, thereby improving manufacturability while maintaining therapeutic effectiveness.
Solution Approach 2:
The core compound structure serves multiple functions: it provides the basic Pin1 inhibition mechanism, acts as a scaffold for various substituent groups, and can be adapted to different therapeutic applications (cancer, inflammatory diseases, metabolic diseases). This multi-functionality reduces the need for entirely separate synthesis routes for different applications.
3Reliability
If Pin1 is overexpressed in cancer cells, then tumor growth and metastasis are promoted, but the lack of effective inhibitors limits treatment options
Solution Approach 1:
The patent develops a universal Pin1 inhibition platform (formula 1) that can be applied across multiple disease types (cancer, inflammatory diseases, metabolic diseases). This single inhibitory mechanism addresses the overexpression of Pin1 in various pathological conditions, providing versatile treatment options rather than requiring disease-specific inhibitors.
Solution Approach 2:
By systematically varying substituent parameters (R1-R6, Ar, L1-L3) in the core structure, the patent generates a library of compounds with different binding affinities and selectivities. This parameter variation provides multiple treatment options targeting Pin1 overexpression in different disease contexts, adapting the same basic mechanism to various therapeutic needs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits Pin1, providing a therapeutic agent for cancer, inflammatory diseases, and metabolic diseases by targeting the enzyme's role in these conditions.
Implementation Method 1
Pin1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1), a proryl isomerase, is an enzyme that catalyzes the cis/trans isomerization of a proline residue amide by binding to the phosphorylated Ser/Thr-Pro site
Data Source
AI summary
The present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing the same as an active ingredient. The method for preparing a biomaterial to which a compound represented by formula 2 is coupled, of the present invention, allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient. In addition, the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.